3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
6
Neuroendocrine Tumors
5
Neoplasm Metastasis
3
Carcinoma, Renal Cell
3
Tuberous Sclerosis
2
Triple Negative Breast Neoplasms
2
Recurrence
2
Glioma
2
Endometrial Neoplasms
2
Adenoma, Islet Cell
2
von Hippel-Lindau Disease
1
Vascular Malformations
1
Unilateral Breast Neoplasms
1
Thymus Neoplasms
1
Seizures
1
Sarcoma, Kaposi
1
Sarcoma
1
Nevus
1
Myelodysplastic Syndromes
1
Multiple Endocrine Neoplasia Type 1
1
Metastatic Digestive System Neuroendocrine Tumor G1
1
Meningioma
1
Lymphangioma
1
Liposarcoma
1
Leukemia, Myeloid, Acute
1
Leiomyosarcoma
1
Kidney Neoplasms
1
Hemangioma
1
Hemangioendothelioma
1
Hamartoma Syndrome, Multiple
1
Interventions
Injections
3
Cytarabine
3
pegylated granulocyte colony-stimulating factor
2
Decitabine
2
Daunorubicin
2
Cladribine
2
Biopsy
2
Azacitidine
2
venetoclax
1
ruxolitinib
1
fludarabine phosphate
1
fedratinib
1
enasidenib
1
Whole-Body Irradiation
1
Tacrolimus
1
Spinal Puncture
1
Specimen Handling
1
Peripheral Blood Stem Cell Transplantation
1
Mycophenolic Acid
1
Mitoxantrone
1
Liposomes
1
Gemtuzumab
1
Cyclophosphamide
1
CPX-351
1
Bone Marrow Transplantation
1
2'-chloro-2'-deoxyadenosine
1
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Leukemia, Monocytic, Acute
×
Everolimus
×
90 days
×
Clear all
No trials found.